Both authors are members of the EuroKUP consortium (www.eurokup.org).
CE-MS in biomarker discovery, validation, and clinical application†
Article first published online: 11 NOV 2010
Copyright © 2011 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim
PROTEOMICS - Clinical Applications
Special Issue: Reviews 2011
Volume 5, Issue 1-2, pages 9–23, February 2011
How to Cite
Mischak, H. and Schanstra, J. P. (2011), CE-MS in biomarker discovery, validation, and clinical application. Prot. Clin. Appl., 5: 9–23. doi: 10.1002/prca.201000058
Colour Online: See the article online to view Figs. 1–6 in colour.
- Issue published online: 31 JAN 2011
- Article first published online: 11 NOV 2010
- Accepted manuscript online: 5 OCT 2010 09:11AM EST
- Manuscript Accepted: 7 SEP 2010
- Manuscript Revised: 3 SEP 2010
- Manuscript Received: 25 JUN 2010
- EU Funding through InGenious HyperCare. Grant Number: LSHM-C7-2006-037093
- SysKID. Grant Number: HEALTH–F2–2009–241544
- Inserm, the “Direction Régional Clinique” (CHU de Toulouse, France) under the Interface program
- Fondation pour la Recherche Médicale
- ANR. Grant Number: ANR-07-PHYSIO-004-01
CE coupled MS (CE-MS) has become an increasingly employed technology in proteome analysis with focus on the identification of biomarker peptides in clinical proteomics. In this review, we will cover technical aspects of CE-MS coupling and highlight the improvements made in the last few years. We examine CE-MS from an application point of view, and evaluate its merits and vices for biomarker discovery and clinical applications. We discus the principal theoretical and practical obstacles encountered when employing CE-MS (and most other proteomic technologies) for the analysis of body fluids for biomarker discovery. We will present several examples of a successful application of CE-MS for biomarker discovery, implications for disease diagnosis, prognosis, and therapy evaluation, and will discuss current challenges and possible future improvements.